Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Acquisitions & Divestments: 2019-2024

Historic Change in Acquisitions & Divestments for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $233.2 million.

  • C4 Therapeutics' Change in Acquisitions & Divestments fell 25.52% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.2 million, marking a year-over-year decrease of 11.09%. This contributed to the annual value of $233.2 million for FY2024, which is 19.56% down from last year.
  • As of FY2024, C4 Therapeutics' Change in Acquisitions & Divestments stood at $233.2 million, which was down 19.56% from $290.0 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Change in Acquisitions & Divestments registered a high of $349.7 million during FY2021, and its lowest value of $104.0 million during FY2020.
  • Over the past 3 years, C4 Therapeutics' median Change in Acquisitions & Divestments value was $283.4 million (recorded in 2022), while the average stood at $268.9 million.
  • Per our database at Business Quant, C4 Therapeutics' Change in Acquisitions & Divestments surged by 236.23% in 2021 and then fell by 19.56% in 2024.
  • Over the past 5 years, C4 Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $104.0 million in 2020, then soared by 236.23% to $349.7 million in 2021, then fell by 18.94% to $283.4 million in 2022, then rose by 2.30% to $290.0 million in 2023, then dropped by 19.56% to $233.2 million in 2024.